LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "non igm" as a keyword



Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma.

Sign Up to like & get
recommendations! Published in 2025 at "Seminars in hematology"

DOI: 10.1053/j.seminhematol.2025.04.002

Abstract: Approximately 95% of lymphoplasmacytic lymphomas (LPL) are IgM secreting and are characterized as Waldenstrom Macroglobulinemia (WM). Conversely, non-IgM secreting LPL are rare. As part of the 12th International Workshop on WM (IWWM-12), a consensus panel… read more here.

Keywords: igm lpl; panel; non igm; consensus ... See more keywords
Photo by nci from unsplash

Efficacy of bortezomib in non‐IgM type I cryoglobulinaemic vasculitis: a single‐centre retrospective case series

Sign Up to like & get
recommendations! Published in 2018 at "European Journal of Haematology"

DOI: 10.1111/ejh.13154

Abstract: Treatment of non‐IgM type I cryoglobulinaemic vasculitis (CV) is challenging. Corticosteroids are first‐line therapy, but relapses are frequent leading to therapeutic escalation. Bortezomib is a proteasome inhibitor with rapid effect on monoclonal component. However, its… read more here.

Keywords: cryoglobulinaemic vasculitis; non igm; type cryoglobulinaemic; igm type ... See more keywords

Waldenström macroglobulinemia and non-IgM-type lymphoplasmacytic lymphoma are genetically similar.

Sign Up to like & get
recommendations! Published in 2023 at "Acta haematologica"

DOI: 10.1159/000530100

Abstract: Introduction Waldenström macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphoma (LPL) with the immunoglobulin (Ig)M paraprotein. MYD88 L265P and CXCR4 mutations are common mutations in WM patients, and mutations in ARID1A and KMT2D (MLL2) have… read more here.

Keywords: non igm; type lpl; igm type;

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-5374

Abstract: Introduction Zanubrutinib (ZANU), a second-generation BTK inhibitor, was approved in 2021 for the treatment of Waldenström macroglobulinemia (WM) based on the ASPEN study. Non-IgM-secreting lymphoplasmacytic lymphoma (LPL), a rare variant comprising 2–5% of LPL cases,… read more here.

Keywords: lpl; treatment; non igm; response ... See more keywords